Computational Algorithms and Large-Scale Data for CAR T Cell Therapy Resistance
Chimeric antigen receptor T (CAR T) cells have become an important and novel therapy for patients with B cell malignancies, mainly due to recent advances in gene, protein, and cell engineering. However, the success of CAR T cell treatment in solid tumors has been minimal. Additional consideration of the factors that shape the response and resistance is needed for driving the development of next-generation CAR T cell therapies to increase efficacy in both hematological malignancies and solid tumors.
This review will discuss the major factors that result in resistance to CAR T cell therapy and how data-driven computational approaches can help identify genes, proteins, and small molecules that can boost engraftment, expansion, and persistence of CAR T cells.View all resources